Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simon Chowdhury

Showing results (111-120 of 151) with videos related to

Pageof 16
Sort By:
Nature Communications|May 6, 2020
Genomic landscape of platinum resistant and sensitive testicular cancersChey Loveday, Kevin Litchfield, Paula Z Proszek, et al.
BMC Medical Imaging|November 16, 2019
Localising occult prostate cancer metastasis with advanced imaging techniques (LOCATE trial): a prospective cohort, observational diagnostic accuracy trial investigating whole-body magnetic resonance imaging in radio-recurrent prostate cancerSola Adeleke, Arash Latifoltojar, Harbir Sidhu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 9, 2021
Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance MechanismsHanna Tukachinsky, Russell W Madison, Jon H Chung, et al.
JCO Precision Oncology|January 20, 2022
Genomic Profiles of De Novo High- and Low-Volume Metastatic Prostate Cancer: Results From a 2-Stage Feasibility and Prevalence Study in the STAMPEDE TrialClare Gilson, Fiona Ingleby, Duncan C Gilbert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 14, 2017
Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell CarcinomaRobert J Motzer, Naomi B Haas, Frede Donskov, et al.
Cancer|December 20, 2025
Association of race and survival in patients treated with apalutamide: Pooled analysis of two phase 3 trialsGeorges Gebrael, Neeraj Agarwal, Alicia K Morgans, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 17, 2013
The effect of VEGF-targeted therapy on biomarker expression in sequential tissue from patients with metastatic clear cell renal cancerKevin Sharpe, Grant D Stewart, Alan Mackay, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 16, 2020
Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a <i>BRCA1</i> or <i>BRCA2</i> Gene AlterationWassim Abida, Akash Patnaik, David Campbell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 2, 2021
Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 StudyAndrea Loehr, Akash Patnaik, David Campbell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 23, 2020
Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 StudyWassim Abida, David Campbell, Akash Patnaik, et al.
Pageof 16

Showing results (111-120 of 151) with videos related to

Sort By:
Pageof 16
Nature Communications|May 6, 2020
Genomic landscape of platinum resistant and sensitive testicular cancersChey Loveday, Kevin Litchfield, Paula Z Proszek, et al.
BMC Medical Imaging|November 16, 2019
Localising occult prostate cancer metastasis with advanced imaging techniques (LOCATE trial): a prospective cohort, observational diagnostic accuracy trial investigating whole-body magnetic resonance imaging in radio-recurrent prostate cancerSola Adeleke, Arash Latifoltojar, Harbir Sidhu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 9, 2021
Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance MechanismsHanna Tukachinsky, Russell W Madison, Jon H Chung, et al.
JCO Precision Oncology|January 20, 2022
Genomic Profiles of De Novo High- and Low-Volume Metastatic Prostate Cancer: Results From a 2-Stage Feasibility and Prevalence Study in the STAMPEDE TrialClare Gilson, Fiona Ingleby, Duncan C Gilbert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 14, 2017
Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell CarcinomaRobert J Motzer, Naomi B Haas, Frede Donskov, et al.
Cancer|December 20, 2025
Association of race and survival in patients treated with apalutamide: Pooled analysis of two phase 3 trialsGeorges Gebrael, Neeraj Agarwal, Alicia K Morgans, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 17, 2013
The effect of VEGF-targeted therapy on biomarker expression in sequential tissue from patients with metastatic clear cell renal cancerKevin Sharpe, Grant D Stewart, Alan Mackay, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 16, 2020
Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a <i>BRCA1</i> or <i>BRCA2</i> Gene AlterationWassim Abida, Akash Patnaik, David Campbell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 2, 2021
Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 StudyAndrea Loehr, Akash Patnaik, David Campbell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 23, 2020
Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 StudyWassim Abida, David Campbell, Akash Patnaik, et al.
Pageof 16